Precision Biosciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Precision BioSciences' 2025 Annual Report reveals a significant net loss and revenue decline, offset by promising clinical advancements in its gene editing pipeline and a successful capital raise.
NASDAQ
10-K: Precision BioSciences Reports Progress in Gene Editing Pipeline and Financial Results for 2024
Precision BioSciences advances its in vivo gene editing therapies, including PBGENE-HBV clinical trial initiation, and reports a net income of $7.2 million for the year ended December 31, 2024.
NASDAQ
Precision BioSciences' 10-K filing highlights a strategic shift towards in vivo gene editing, divesting its CAR T platform and focusing on its ARCUS technology for genetic and infectious diseases.